Revenue	9 Months Ended
Sep. 30, 2020
Revenue
Revenue	(11) Revenue Product Development and Licensing Revenue The Company entered into an agreement with Rockefeller University in September 2013, as amended, (the “Rockefeller Agreement”) pursuant to which the Company performs manufacturing and development services for Rockefeller University for their portfolio of antibodies against HIV. This portfolio was licensed to Gilead Sciences in January 2020 from Rockefeller University (“Rockefeller Transaction”). Pursuant to the Rockefeller Agreement, the Company received an upfront payment of $1.8 million as a result of the Rockefeller Transaction which was recorded to revenue during the first quarter of 2020. The Company is eligible to receive additional payments from Rockefeller University if this portfolio progresses through clinical and commercial development. Contract and Grants Revenue The Company has entered into the Rockefeller Agreement and an agreement with Duke University pursuant to which the Company performs manufacturing and research and development services on a time-and-materials basis or at a negotiated fixed-price. The Company recognized $0.2 million and $0.7 million in revenue under these agreements during the three and nine months ended September 30, 2020, respectively, and $0.4 million and $1.9 million during the three and nine months ended September 30, 2019, respectively. During the quarter ended September 30, 2020, the Company was awarded a Small Business Innovation Research (“SBIR”) grant from the National Institutes of Health (NIH) to support the Company's CDX-1140 and CDX-301 programs. The Company recognized $0.3 million in grant revenue under the award during the three months ended September 30, 2020. Contract Assets and Liabilities At December 31, 2019 and September 30, 2020, the Company’s right to consideration under all contracts was considered unconditional, and as such, there were no recorded contract assets. At December 31, 2019 and September 30, 2020, the Company had $0.3 million and $0.6 million in contract liabilities recorded, respectively. Revenue recognized from contract liabilities as of December 31, 2019 during the three and nine months ended September 30, 2020 was $0.0 million and $0.2 million, respectively.

(11) Revenue

Product Development and Licensing Revenue

The Company entered into an agreement with Rockefeller University in September 2013, as amended, (the “Rockefeller Agreement”) pursuant to which the Company performs manufacturing and development services for Rockefeller University for their portfolio of antibodies against HIV. This portfolio was licensed to Gilead Sciences in January 2020 from Rockefeller University (“Rockefeller Transaction”). Pursuant to the Rockefeller Agreement, the Company received an upfront payment of $1.8 million as a result of the Rockefeller Transaction which was recorded to revenue during the first quarter of 2020. The Company is eligible to receive additional payments from Rockefeller University if this portfolio progresses through clinical and commercial development.

Contract and Grants Revenue

The Company has entered into the Rockefeller Agreement and an agreement with Duke University pursuant to which the Company performs manufacturing and research and development services on a time-and-materials basis or at a negotiated fixed-price. The Company recognized $0.2 million and $0.7 million in revenue under these agreements during the three and nine months ended September 30, 2020, respectively, and $0.4 million and $1.9 million during the three and nine months ended September 30, 2019, respectively.

During the quarter ended September 30, 2020, the Company was awarded a Small Business Innovation Research (“SBIR”) grant from the National Institutes of Health (NIH) to support the Company's CDX-1140 and CDX-301 programs. The Company recognized $0.3 million in grant revenue under the award during the three months ended September 30, 2020.

Contract Assets and Liabilities

At December 31, 2019 and September 30, 2020, the Company’s right to consideration under all contracts was considered unconditional, and as such, there were no recorded contract assets. At December 31, 2019 and September 30, 2020, the Company had $0.3 million and $0.6 million in contract liabilities recorded, respectively. Revenue recognized from contract liabilities as of December 31, 2019 during the three and nine months ended September 30, 2020 was $0.0 million and $0.2 million, respectively.